1
Exhibit 10.32
December 17, 1997
X. Xxxxxxx xx Xxxxxx
Secretary General, External Research
Pasteur Merieux Connaught
1541 Av. Xxxxxx Xxxxxxx
69280 Marcy L'Etoile
FRANCE
RE: EXTENDED OPTION TO XXXX
Dear Xxxxxxx:
In accordance with our Letter Agreement dated October 21, 1997, PMC's option to
LeIF (the "Initial Option"), pursuant to the Option and License Agreement
between Corixa and PMC, (the "Initial Option Agreement"), will expire on
December 24, 1997. Based on our discussions, Xxxxxx agrees that, in the event
PMC does not exercise the Initial Option in any of PMC's disease fields on or
before December 24, 1997, Xxxxxx is willing to grant PMC an additional six (6)
month option to LeIF (the "Extended Option"), effective January 1, 1998 through
June 30, 1998. The Extended Option will be granted by Xxxxxx in order to allow
PMC the opportunity for additional analysis of LeIF in accordance with the
Research Plan (the "Plan"), attached hereto as Exhibit A. Under the Plan, PMC
will provide certain research reagents to Corixa for use by Corixa in the LeIF
evaluation to be performed by Corixa under the Plan.
PMC will have the right to exercise the Extended Option in one or more of the
disease fields available to PMC under the Initial Option Agreement by providing
Corixa written notice of exercise on or before June 30, 1998. In the event PMC
exercises the Extended Option, Corixa and PMC shall then enter into a license
agreement on the terms and conditions of the Initial Option Agreement.
2
If the foregoing is acceptable, please sign as indicated below and return a copy
of this letter to my attention.
Best regards,
For CORIXA CORPORATION
/s/ Xxxx XxXxxx
--------------------------------------
Xxxx XxXxxx
Chief Operating Officer
Agreed and Accepted by
PASTEUR MERIEUX Serums & Vaccins S.A.
/s/ Xxxxxxx xx Xxxxxx
--------------------------------------
Xxxxxxx xx Xxxxxx
Secretary General, External Research
-2-
3
LeIF Rresearch Plan
1998
[xxx]
